Concr does not have any job openings currently. Please submit your details to be considered for future roles.
About Us
At Concr, we are on a mission to solve data to enable precision therapeutics for all. We are a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies.
Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding the most accurate multi-modal tumour models. Concr’s cloud native platform – FarrSight® – empowers researchers to computationally simulate clinical trials, make advanced predictions about therapeutic response and biomarkers, and perform standard bioinformatics analyses directly. We do this by combining cutting-edge machine learning techniques with a deep scientific understanding of tumour progression to accurately predict cancer evolution in response to treatment.
Concr aims to:
- Accelerate life-saving innovation to reach the clinic
- Cut the cost of cancer treatment
- Reduce treatment resistance
- Enable proactive treatment adaptation
- Save lives
How to Apply
Please attach your CV, any relevant portfolio and a cover letter. The cover letter should explain:
- The reason for your interest in working with Concr
- What you can bring to the table in terms of hard and soft skills
- A personal development goal if there is any you are comfortable sharing
Thank you for your interest in Concr and taking the time to submit your details.
Sincerely
Emre Misirlioglu
COO
What We Do
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom
